← Leaderboards
Dan Angress
Cicerodx, Inc.
$1,126,084
Attributed
$1,126,084
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $512.8K · FY2019–21$1M$750K$500K$250K$0
'19
'20
'21
Funding mix
By agency
NIH$1,126,084 · 1
By mechanism
R44$1,126,084 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Evaluation”
- Valerie Koch · University Corporation For Atmospheric Res$265,601,376
- Leonard Freedman · Leidos Biomedical Research, Inc.$241,645,551
- Beth Baseler · Leidos Biomedical Research, Inc.$208,220,586
- John E West · University Of Texas At Austin$131,399,667
- Kimberly Smith · Ppd Development Lp$115,671,664
- Lynn Briscoe · Leidos Biomedical Research, Inc.$95,805,377
Research focus
EvaluationFunctional DisorderEndometriosisEstrogensBaseFailureArchivesEndometrialBiopsyAgedBloodCervicalBcl6 GeneChronic Pelvic PainClinical ApplicationBenignConsensusBiological MarkersDiagnosisDiagnosis EvaluationDiagnostic TestsDysmenorrheaEarly DiagnosisFuture
Grant awards (3)
SIRT1 and BCL6: Dual Biomarkers of Endometriosis and Endometrial Receptivity$463,322
R44 · FY2021 · HD · contact PI
SIRT1 and BCL6: Dual Biomarkers of Endometriosis and Endometrial Receptivity$512,762
R44 · FY2020 · HD · contact PI
SIRT1 and BCL6: Dual Biomarkers of Endometriosis and Endometrial Receptivity$150,000
R44 · FY2019 · HD · contact PI